The present application relates to pharmaceutical compositions for reducing glucose excursions in a normal subject or a subject having an insulin-related disorder or dysglycemia. The pharmaceutical composition contains one or more active agent-containing layers, which each contain a dry blended mixture including a therapeutically effective amount of a polar ionizable insulin-sensitizing oral hypoglycemic agent or a pharmaceutically acceptable salt thereof, and an amphipathic compound in monomelic form consisting of an amphipathic ionic compound in monomelic form. Each dry blended mixture contains a sufficient amount of the amphipathic ionic compound such that upon contact with an aqueous fluid, the amphipathic ionic compound forms a reverse micelle comprising the polar ionizable insulin-sensitizing oral hypoglycemic agent. The present invention also relates to a use of a modified release pharmaceutical composition comprising a therapeutically effective amount of an insulin-sensitizing oral hypoglycemic agent for sensitizing pre-prandial (basal) insulin levels and/or reducing postprandial glucose excursions in a normal patient or a patient having an insulin-related disorder.
